Harpoon raises $70M ahead of additional Phase I starts for TriTACs

Harpoon Therapeutics Inc. (South San Francisco, Calif.) raised $70 million on Nov. 11 in a series C round led by new investor OrbiMed Advisors, as the immunotherapy company gears

Read the full 292 word article

User Sign In